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INFLUENCING PRESCRIBING IN ENGLISH
PRIMARY CARE: FINDINGS FROM THE MANMED
SURVEY
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Economics, London, United Kingdom; 3South Manchester
University Hospitals NHS Trust, Manchester, United Kingdom
OBJECTIVES: Over the last 3 decades, expenditure on
medicines in the UK has increased in real terms by almost
5-fold and currently forms about 12% of all NHS expen-
diture. The MANMED (MANagement of MEDicines)
survey was designed to explore how medicines are cur-
rently managed in the NHS in England. METHODS: In
May 2001, a postal survey was sent to prescribing advis-
ers and prescribing leads in 332 Primary Care Organisa-
tions (PCO) and to chief pharmacists at 275 NHS
hospital Trusts (NHSTs). RESULTS: Sixty-six percent of
PCOs and 57% of NHSTs responded to the MANMED
survey. Most PCOs report quality of prescribing as their
top priority, followed by budget adherence at both prac-
tice and PCO levels. Prescribing advisers offer an average
of 6.6 forms of support (range: 3–9), including the review
of prescribing patterns (95% of respondents), practice
visits (95%), visits to individual GPs (92%), indicators of
prescribing performance (92%) and prescribing newslet-
ters (88%). PCOs are pursuing a wide range of pres-
cribing initiatives, covering an average of 7 different
therapeutic areas, including proton pump inhibitors
(82%), antibacterials (76%), generics (76%) and statins
(62%). National targets are the main driver for prescrib-
ing initiatives, but other key inﬂuences include inappro-
priate prescribing and clinical governance. Prescribing
incentive schemes commonly include generics targets
(81%), audits (64%) and reviews of repeat prescribing
(58%). PCO involvement with secondary care varies: one
third of PCO prescribing committees include a hospital
pharmacist, and just 7% include a hospital consultant.
However, evidence from the MANMED (NHST) survey
suggests that most PCOs are represented on their local
NHST Drug and Therapeutics committee. CONCLU-
SIONS: It would appear that while cost considerations
are important, quality is perceived as the overriding prin-
ciple on which PCO prescribing strategy is based. Multi-
faceted prescribing support is widespread and national
targets are the main factor inﬂuencing choice of thera-
peutic area for prescribing initiatives.
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MANAGING THERAPEUTICS NOVELTIES USING
A SCIENTIFIC EVIDENCE-BASED METHOD
Catalan A, Perez MT, Gene J
Catalonian Health Institute, Barcelona, Spain
OBJECTIVES: At primary care, few new drugs (ND) add
value to Spanish drug formulary. Here we deﬁne a global
strategy focused to improve the general practitioner’s
(GPs) ND prescription habit. METHODS: Our strategy
is composed by two interventions and is focused on GP.
The interventions are: Generalised Intervention (GI) and
Speciﬁc Intervention (SI). A New Drugs Evaluation Com-
mittee (NDEC) guided by an evidence-based standardised
procedure, compared every ND in terms of efﬁcacy,
safety, posology (pharmacology??) and cost versus the
best pharmaceutical option for the same indication. By
means of a decision-making algorithm, ND were cate-
gorised as important, modest or null therapeutic improve-
ment. NDEC has external peer review. The NDEC
prepared an extensive evaluation and a reduced evalua-
tion. They were posted at the institution’s web and the
reduced evaluation was sent to GPs by post. The Speciﬁc
Intervention (SI) was activated when a ND was negatively
evaluated and the ND had a persistent high market share.
SI is an academic visit (face-to-face) between a pharma-
ceutical adviser and each GP, who is a constant prescriber
of the ND. We monitored the consumption of ND for two
years (2000–2001), using the same information from the
Madrid community (out of Catalonian) as a reference.
RESULTS: 85% of the 16 ND evaluated are in the “little
or null therapeutic improvement” category. The Cat-
alonian GPs had a lower ND utilisation rate than the
Madrid GPs (57% vs. 120%) and the reduction of the
utilisation tendency observed along 2001 was higher
(15% vs. 10%) in a biannual rate. On September 2001
the SI was activated for two drugs, ROFECOXIB 
and CELECOXIB (1,7% market share of pharmaceutical
sales). We interviewed 1000GPs and obtained a 35%
reduction in their prescribing. CONCLUSIONS: It’s pos-
sible to change the use of ND using evidence-based drug
information and a combined diffusion strategy of gener-
alized and one-on-one interventions.
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THE USE OF PATHOLOGY-RELATED
PARAMETERS IN EXPLAINING THE VARIATION
OF PUBLIC EXPENDITURES ON MEDICAL
IMAGING
Puttevils D, Ooms D,Wissels G, Putman K, Corens D,
Beeckmans J
Free University Brussels, Brussels, Belgium
OBJECTIVES: In order to allocate public resources on
health care more efﬁciently, lump sum based payment
systems are introduced in the Belgian hospital sector. This
study investigates the inﬂuence of pathology-related para-
meters on the consumption of medical imaging. A regres-
sion based method (ANCOVA) is used to deﬁne an
explanatory model for the expenditure on medical
imaging. METHODS: A representative sample of 30 hos-
pitals was withdrawn from the national data. This sample
contains 277.521 inpatient stays (19% of total), all of
which related to data on utilisation of resources as well
as data concerning the pathology. The pathology-related
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data consist, amongst others, of Diagnostic Related
Groups (DRG), severity of illness, risk of mortality,
number of procedures and comorbidity. Regression
analysis was used to estimate the impact of these pathol-
ogy-related parameters on the use of resources for
medical imaging. RESULTS: All pathology-related 
parameters have a statistically signiﬁcant impact on 
the consumption of medical imaging. Fifty-seven and
three–tenths percent of the case wise variation in utilisa-
tion of resources can be explained by the different para-
meters. However, the interaction of DRG with the
severity of illness in itself explains 46.7% of this varia-
tion. CONCLUSIONS: Pathology-related parameters,
especially the interaction of DRG with the severity of
illness, can be used to determine a lump sum fee that
could partly (+/-50%) replace the in essence fee for
service based payment system currently in practice.
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GENERIC DRUG PRICES ARE TYPICALLY
HIGHER IN CANADA THAN IN THE UNITED
STATES
Palmer WN, D’Angelo J
Palmer D’Angelo Consulting Inc, Ottawa, ON, Canada
OBJECTIVE: This paper compares the prices of top
selling generic drugs in Canada with prices for compara-
ble generic products in the United States. METHODS:
The research examined the prices of 27 top selling (in
2001) generic prescription medicines in Canada that were
marketed in both Canada and the United States. The
sample represented approximately 36% of total generic
sales in Canada. For each of the generic medicines a 
representative presentation (strength/dosage form) was
selected—generally the top selling presentation of the
medicine. The prices were the Q1 2002 Canadian ex-
factory prices as listed in the Québec provincial govern-
ment formulary and the US Federal Supply Schedule (FSS)
prices. These prices generally represent the best available
prices in the two countries. RESULTS: Preliminary results
indicate that of the 27 leading generic drug products
examined, 21 had higher prices in Canada than in the
U.S. By all measures Canadian generic prices of the
sample drugs were higher than those in the U.S.: Mean:
+155%; Weighted Mean: +37%; Median +51%. Annual
savings in excess of C$150 million would result if 
Canadians had access to FSS prices for the sample drugs.
If the price differences seen in the sample can be extrap-
olated to all generic drugs available in Canada, the poten-
tial annual savings would exceed C$400 million.
CONCLUSIONS: It is generally accepted that the ex-
factory prices of innovator (brand name) prescription
drugs are signiﬁcantly lower in Canada than in the United
States. It was therefore surprising to ﬁnd the opposite
result for generic drugs. Several factors may contribute to
higher Canadian generic prices. The Canadian generic
industry is highly concentrated (relative to the US) with
the market dominated by two large generics ﬁrms. Sec-
ondly, provincial government reimbursement policies dis-
courage discounting and feature published formularies
that typically establish ex-factory prices for all classes of
customer.
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SPANISH NATIONAL HEALTH SERVICE (NHS):
PHARMACEUTICAL CONSUMPTION AND
ESTIMATION OF THE SAVING WITH GENERIC
DRUG PRESCRIPTIONS
Gaspar D, Mariño E
University of Barcelona, Barcelona, Spain
OBJECTIVES: Spanish Health Administration has devel-
oped some regulatory actions to check the growth of
drugs expenditure. Speciﬁcally, in 1999, Government
approved a reference price system for many drug groups
(homogeneous). Here, we present the initial data from a
study of drug consumption and a estimation of the saving
with the prescriptions of generic drugs. METHODS:
This study was divided into 2 periods: 1990–1998 and
1999–2002. In the second, the inﬂuence of the reference
price system implementation will be observed. Data from
Spanish NHS about drug consumption were provided by
the Ministry of Health and Consumer Affairs. We elabo-
rated our own database. Consumption was expressed as
PVP (price for sale direct to costumer, tax-free) by means
of PTAM (Peseta Millions) or €M (Euro Millions), and
was revised through CPI (Consumption Price Indexes,
Base 1990). Information about PVP drugs was obtained
from Ofﬁcial Drug Directory. DID (Dose for thousand
inhabitants and for day) was also calculated according to
DDD’s standard—Nordic Council Medicines ATC/DDD,
edition 1998. Saving estimation was calculated through
PVP minimum criteria of prescription, since the reference
price system had not been implemented yet. RESULTS:
According to consumption data obtained, in 1998, top
four therapeutic groups—29 active principles—explained
almost 34% of the whole expense—286116.2 PTAM or
2458.33 €M. Besides, if the criterion of PVP minimum
was applied, for the most usual format (package) per pre-
scription, the average saving would be almost 7%. In the
Spanish pharmaceutical market there are many prices for
speciﬁc active principles, being possible to identify the
biggest individual saving. CONCLUSIONS: Almost the
third part of NHS pharmaceutical budget in 1998 was
assigned at 29 active principles. The level of individual
saving was signiﬁcant in omeprazole (44%) or famotidine
(40%), among others.
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